Rapport therapeutics reports fourth quarter and full year 2024 financial results and provides business update

Results of positron emission tomography (pet) trial and second multiple ascending dose (mad-2) trial support rap-219's transformative potential for epilepsy and other central nervous system (cns) disorders continued momentum in the phase 2a trial of rap-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025 expect to initiate a phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  appointed recognized translational and clinical drug development leader, jeffrey sevigny, m.d., as chief medical officer  ended the year with $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 boston and san diego, march 11, 2025 (globe newswire) -- rapport therapeutics, inc. (nasdaq: rapp) (“rapport” or the “company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter and full year ended december 31, 2024, and provided a business update.
RAPP Ratings Summary
RAPP Quant Ranking